May 7 |
Precision BioSciences to Report First Quarter Results on May 13, 2024
|
May 7 |
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
|
May 1 |
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
|
Apr 17 |
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
|
Apr 16 |
Eli Lilly subsidiary, Precision Biosciences end gene therapy collaboration
|
Apr 16 |
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
|
Apr 11 |
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
|
Apr 2 |
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know
|
Apr 2 |
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
|